Adaptimmune therapeutics plc ( afami-cel ) is a cell therapy company that has received tremendous support for afami-cel from healthcare providers and patients. in 2022, we are focused on four things to drive value for our stakeholders : one submitting the biomarker for afami-cel in the second quarter of this year ; two  building out the molecular target for mage-a4 and four progressing our allogeneic platform. we are on track to submit our first biomarker for the treatment of synovial sarcoma in Q4, and denn is going to update them on our progress towards submission.